Skip to content

The outlook for Chinese equities in 2026 is bright. Its ability to stand up to US trade demands reflects the narrowing technological gap between the two economies. We anticipate a less confrontational approach towards trade in 2026 as both sides seek to focus on growing their economies.

Market themes in 2026 include: rising corporate margins driven by anti-involution policies reducing unsustainable competition; increasing power demand as China’s Deepseek moment drives rising investment in data centers, and fiscal stimulus to support growth.

In the year ahead China will release its fifteenth five-year plan focusing on sustainable, efficient and balanced economic growth. We expect emphasis on consumption and innovation compared to investment and green energy in the 14th plan.

Sector beneficiaries in the Plan are expected to include semiconductors, consumer discretionary, power equipment and biotech. Prior plans were a useful roadmap for investors in deciding where to allocate capital.

Earnings and valuations

Consensus expectations for MSCI China 2026 earnings growth is 15%, with 35% forecast growth in the consumer discretionary sector,1 led by China’s internet and delivery platform giants. Anti-involution is expected to reduce unsustainable competition and boost corporate margins in the markets largest sector.

China Sector Earnings Growth 2026 Estimate

Sources: IBES, MSCI, as of 2 December 2025.

MSCI China 2026 price-to-earnings valuation of 12.6x is slightly above the long-term average,2reflecting the 28% gain in the index between January and mid December 2025. Global equity funds are 6.5% underweight China, compared to a post COVID-19 average of 5.5%.3This indicates there is potential for a pick-up in foreign fund inflows, given the prospects for a recovery in margins to drive earnings and still reasonable valuations.

Key themes

Anti-involution is a multi-year theme focusing on a pivot from price competition to quality driven growth. The policy is starting to drive rational competition with 2026 likely to bring about increased consolidation in sectors with over capacity. This is positive for corporate margins and return on equity, with large companies expected to be the biggest beneficiaries.

Deepseek moment. The release of Deepseek’s large language model in January 2025 shook the technology world. Its efficiency4 and use of open-source software gives it an edge in an environment where the needs of power hungry proprietary models are colliding with constrained power grids. China’s monthly token use in AI models is forecast to be in a range of 220-670Qa between from 2025 to 2030, compared to between 100-175Qa in the US.5 This is expected to require significant data center and in turn power investment.

Local governments in Gansu, Guizhou and Inner Mongolia have lowered power prices for data centers using domestically produced chips. This is a clear signal that China is prioritising growth of domestic AI models, with positive implications for power equipment suppliers.

China and US Hyperscaler Token Usage 2025 & 2030

Sources: Microsoft, Alphabet, Amazon. As of 1 December 2025.

Fiscal stimulus. The central government will increase bond issuance by CNY1Tn in 2026, with supply front loaded to the start of the year. The fiscal deficit is expected to increase to 4% of GDP. The stimulus will focus on boosting consumption and targeted support for innovation in sectors including semiconductors and those with high import content.

Sector views

China Sector Performance 2025

Sources: Bloomberg, MSCI, as of 2 December 2025.

Technology. China continues to close the technology gap with the US in the semiconductor sector. Technological independence remains a priority with the government committed to removing non Chinese software and replacing it with domestically developed solutions. Developing domestic ecosystems creates the potential for an alternative global AI supply chain. This may provide export opportunities to Belt and Road countries where China has already had success in exporting green technologies and electric vehicles.

Consumer discretionary. The impact of anti-involution is expected to be positive on the sector as companies pivot from competing solely on price to a focus on quality. We expect this to be positive for corporate margins as reflected in the 35% consensus earnings growth forecast for the sector. We remain positive on Chinese internet platform companies, viewing anti-involution as a positive catalyst.

Industrials. We are focused on the Chinese power equipment sector as the prime beneficiary in the growth in power demand for data centers and the replacement of ageing equipment globally. The IEA is forecasting the installed power base for data centers globally to increase by >20% annually between 2025–28. Given the capacity constraints in Europe and the US, Chinese power equipment companies have the potential to increase market share given their cost efficient, scalable solutions.

Health care. The Chinese biotech sector is witnessing significant growth, we are focused on oncology where China has witnessed a rise in its share of global trials to 39% in 2024 from 5% in 2014.6 The international acceptance of Chinese clinical data has increased investor confidence towards the sector. In particular its success in non-small cell lung cancer trials, which was validated in a study published in The Lancet medical journal in 2024.

China’s advantages in Biotech include:

  • Labour costs
  • Economies of scale
  • Supply chain
  • Government support
  • Cost effective R&D and patient trials.

The outlook for Chinese equities in 2026 is bright. Catalysts to drive the market higher include the positive effect of anti-involution on unsustainable competition. This has the potential to increase margins and drive consensus forecasts of 15% earnings growth. We are positive on the semiconductor, consumer discretionary, power equipment and biotech sectors.



IMPORTANT LEGAL INFORMATION

This material is intended to be of general interest only and should not be construed as individual investment advice or a recommendation or solicitation to buy, sell or hold any security or to adopt any investment strategy. It does not constitute legal or tax advice. This material may not be reproduced, distributed or published without prior written permission from Franklin Templeton.

The views expressed are those of the investment manager and the comments, opinions and analyses are rendered as at publication date and may change without notice. The underlying assumptions and these views are subject to change based on market and other conditions and may differ from other portfolio managers or of the firm as a whole. The information provided in this material is not intended as a complete analysis of every material fact regarding any country, region or market. There is no assurance that any prediction, projection or forecast on the economy, stock market, bond market or the economic trends of the markets will be realized. The value of investments and the income from them can go down as well as up and you may not get back the full amount that you invested. Past performance is not necessarily indicative nor a guarantee of future performance. All investments involve risks, including possible loss of principal.

Any research and analysis contained in this material has been procured by Franklin Templeton for its own purposes and may be acted upon in that connection and, as such, is provided to you incidentally. Data from third party sources may have been used in the preparation of this material and Franklin Templeton ("FT") has not independently verified, validated or audited such data.  Although information has been obtained from sources that Franklin Templeton believes to be reliable, no guarantee can be given as to its accuracy and such information may be incomplete or condensed and may be subject to change at any time without notice. The mention of any individual securities should neither constitute nor be construed as a recommendation to purchase, hold or sell any securities, and the information provided regarding such individual securities (if any) is not a sufficient basis upon which to make an investment decision. FT accepts no liability whatsoever for any loss arising from use of this information and reliance upon the comments, opinions and analyses in the material is at the sole discretion of the user.

Franklin Templeton has environmental, social and governance (ESG) capabilities; however, not all strategies or products for a strategy consider “ESG” as part of their investment process.

Products, services and information may not be available in all jurisdictions and are offered outside the U.S. by other FT affiliates and/or their distributors as local laws and regulation permits. Please consult your own financial professional or Franklin Templeton institutional contact for further information on availability of products and services in your jurisdiction.

Issued in the U.S. by Franklin Templeton, One Franklin Parkway, San Mateo, California 94403-1906, (800) DIAL BEN/342-5236, franklintempleton.com. Investments are not FDIC insured; may lose value; and are not bank guaranteed.

You need Adobe Acrobat Reader to view and print PDF documents. Download a free version from Adobe's website.

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.